Skip to content

Kirran Ahmad

5 papers in the library · 37 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

bioRxiv (Cold Spring Harbor Laboratory) October 13, 2026 Claudio Agnorelli, Joseph Peill, Danielle Kurtin et al. preprint

Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human...

Psilocybin therapy for adult females with anorexia nervosa: pilot study.

The British Journal of Psychiatry July 8, 2026 Hannah Douglass, Meg J. Spriggs, Kate Godfrey et al.

Background Anorexia nervosa is a debilitating eating disorder with high mortality and chronicity rates owing to the paucity of effective existing treatments. Several clinical trials using psilocybin therapy have demonstrated therapeutic efficacy and safety in psychiatric conditions, including anorexia nervosa. Aims This study aimed to further assess the safety, feasibility and potential...

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

Journal of Cerebral Blood Flow & Metabolism March 21, 2026 Claudio Agnorelli, Joseph Peill, Gabriela Sawicka et al.

We investigated ketamine's neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1-8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [11C]-UCBJ (synaptic density/plasticity), 1H-MRS (glutamate and GABA) and...

An international Delphi consensus for reporting of setting in psychedelic clinical trials.

Nature Medicine June 3, 2025 Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman et al. 26 citations

Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based...

DOI: 10.1038/s41591-025-03685-9 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Therapeutic protocols Clinical guidelines Mental health treatment +1

Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”

Frontiers in Psychiatry June 4, 2024 Julia Bornemann, James B. Close, Kirran Ahmad et al. 11 citations

Background Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best. Here, we present a protocol for a mechanistic study investigating the effects of psychedelic-assisted-therapy in a fibromyalgia population. The...